Pharmacist Diabetes On-Demand 1h

Tirzepatide is a novel drug that works as an agonist of both GLP-1 and GIP. How does this compare to semaglutide, a GLP-1 agonist? Join us as we discuss the SURPASS-2 trial, and compare the drugs’ mechanisms of action, effect on hemoglobin A1c, impact on weight, and overall clinical outcomes.

This journal club dissects an article from The New England Journal of Medicine – Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. 

Learning Objectives

Upon successful completion of this application-based course, pharmacists and pharmacy students should be able to:
1. Describe the mechanism of action of tirzepatide
2. Compare and contrast tirzepatide with semaglutide
3. Discuss clinical trial data on tirzepatide’s effect on hemoglobin A1c at various doses as compared to semaglutide
4. Discuss the impact of tirzepatide on patient weight
5. Develop a conclusion for tirzepatide’s role in patient-centered diabetes care based on a clinical trial

Faculty

Ellen Jones, PharmD

Assistant Professor
Harding University College of Pharmacy

Disclosures:

Ellen Jones has no relevant financial relationships with ineligible companies to disclose.

Course Details